Status:
COMPLETED
Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation
Lead Sponsor:
Samsung Medical Center
Conditions:
Neuroblastoma
Eligibility:
All Genders
Up to 20 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the feasibility and efficacy of reduced-intensity allogeneic stem cell transplantation (RIST) with RIC regimen in children with neuroblastoma who have failed a...
Detailed Description
The prognosis of high-risk neuroblastoma (NB) after conventional chemoradiotherapy is very poor. Therefore, a strategy using high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-...
Eligibility Criteria
Inclusion
- Patients with NB who have failed a prior auto-SCT will be eligible for the present study. Patients should have no severe comorbid organ dysfunction (NCI grade \> 2 organ toxicity) at enrollment.
Exclusion
- Patients with severe comorbid organ dysfunction (NCI grade \> 2 organ toxicity) prior to RIST will be off the present study.
- Patients with progressed tumor prior to RIST will be off the present study.
- Patients whose parents do not want to undergo RIST will be off the present study.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2015
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00793351
Start Date
September 1 2008
End Date
November 1 2015
Last Update
October 19 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea